DOP2015000175A - Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular - Google Patents

Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular

Info

Publication number
DOP2015000175A
DOP2015000175A DO2015000175A DO2015000175A DOP2015000175A DO P2015000175 A DOP2015000175 A DO P2015000175A DO 2015000175 A DO2015000175 A DO 2015000175A DO 2015000175 A DO2015000175 A DO 2015000175A DO P2015000175 A DOP2015000175 A DO P2015000175A
Authority
DO
Dominican Republic
Prior art keywords
peptide
treat
preparation
vasodilator
medicinal product
Prior art date
Application number
DO2015000175A
Other languages
English (en)
Spanish (es)
Inventor
Johannes Holzmeister
Original Assignee
Cardiorentis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiorentis Ltd filed Critical Cardiorentis Ltd
Publication of DOP2015000175A publication Critical patent/DOP2015000175A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
DO2015000175A 2013-01-25 2015-07-24 Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular DOP2015000175A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361756692P 2013-01-25 2013-01-25

Publications (1)

Publication Number Publication Date
DOP2015000175A true DOP2015000175A (es) 2015-11-15

Family

ID=50382492

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000175A DOP2015000175A (es) 2013-01-25 2015-07-24 Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular

Country Status (19)

Country Link
US (2) US20140213520A1 (enExample)
EP (1) EP2948165A2 (enExample)
JP (1) JP2016505065A (enExample)
KR (1) KR20150108903A (enExample)
CN (1) CN105025918A (enExample)
AP (1) AP2015008624A0 (enExample)
AU (1) AU2014208851B2 (enExample)
BR (1) BR112015017432A2 (enExample)
CA (1) CA2898571A1 (enExample)
DO (1) DOP2015000175A (enExample)
EA (1) EA201500765A1 (enExample)
IL (1) IL239909A0 (enExample)
MX (1) MX2015009606A (enExample)
NZ (1) NZ710246A (enExample)
PH (1) PH12015501559A1 (enExample)
SG (1) SG11201505492XA (enExample)
TN (1) TN2015000315A1 (enExample)
TW (1) TW201442722A (enExample)
WO (1) WO2014115033A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184248A1 (en) * 2014-05-30 2015-12-03 Concert Pharmaceuticals, Inc. Methods of treating fibrotic diseases
CN105617360B (zh) * 2015-12-04 2018-12-21 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CN110278941B (zh) * 2019-07-11 2021-05-28 西安国际医学中心有限公司 一种含有钠尿肽的离体心脏保护液

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5461142A (en) 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
ES2188665T3 (es) 1994-06-02 2003-07-01 Forssmann Wolf Georg Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
NZ525389A (en) * 2000-10-04 2009-04-30 Molecular Medicine Res Inst Methods of modulating apoptosis by administration of relaxin agonists or antagonists
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
WO2006110743A1 (en) * 2005-04-07 2006-10-19 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
US8293711B2 (en) * 2007-09-11 2012-10-23 Pharis Biotech Gmbh Use of natriuretic peptides for treating angioedema syndromes
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
CN104815319A (zh) * 2008-05-16 2015-08-05 科尔泰拉公司 治疗慢性心力衰竭的方法
WO2010048308A2 (en) * 2008-10-24 2010-04-29 Deborah Dickey Natriuretic polypeptides
JP2010116325A (ja) * 2008-11-11 2010-05-27 Institute For Protein Science Co Ltd Ｓｉｒｓ患者を救命するためのペプチド組成物
US20110014180A1 (en) * 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
UY32902A (es) * 2009-09-25 2011-02-28 Alcon Res Ltd Nuevos agonistas de npr-b
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
US20130197188A1 (en) * 2010-03-15 2013-08-01 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
US20120052097A1 (en) * 2010-08-20 2012-03-01 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
NZ710246A (en) 2016-11-25
WO2014115033A3 (en) 2015-02-26
WO2014115033A2 (en) 2014-07-31
JP2016505065A (ja) 2016-02-18
AU2014208851B2 (en) 2016-12-22
CA2898571A1 (en) 2014-07-31
MX2015009606A (es) 2016-04-26
KR20150108903A (ko) 2015-09-30
US20140213520A1 (en) 2014-07-31
AU2014208851A1 (en) 2015-08-06
BR112015017432A2 (pt) 2017-07-11
EA201500765A1 (ru) 2015-12-30
SG11201505492XA (en) 2015-08-28
US20140213519A1 (en) 2014-07-31
TN2015000315A1 (en) 2017-01-03
CN105025918A (zh) 2015-11-04
TW201442722A (zh) 2014-11-16
PH12015501559A1 (en) 2015-09-21
AP2015008624A0 (en) 2015-07-31
IL239909A0 (en) 2015-08-31
EP2948165A2 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
EA201500934A1 (ru) Кардио- и нефропротективная противодиабетическая терапия
MX2017001512A (es) Compuestos activos hacia bromodominios.
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2018000570A (es) Nuevas isoformas de tripsina y su uso.
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
CL2013003003A1 (es) Uso de fórmula infantil que comprende al menos una fuente de proteínas, una fuente de lípidos, una fuente de carbohidratos, con 1,6-1,85 g/100 kcal que sirve para preparar un medicamento útil en la prevención de la presión sanguínea elevada o de las enfermedades cardiovasculares.
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
MX2020003049A (es) Semaglutida en la terapia medica.
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
ECSP16096831A (es) Derivados de naftiridinadiona
CL2018001104A1 (es) Composición para el cuidado de la piel y procedimiento asociado.
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
CO7461127A2 (es) Código para la configuración de un dispositivo de atención al paciente
UY35745A (es) Derivados sustituidos de fenilalanina
DOP2015000175A (es) Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular